Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026 [Seeking Alpha]
Fennec Pharmaceuticals Inc. (FENC)
Last fennec pharmaceuticals inc. earnings: 11/12 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.fennecpharma.com/investor-relations
Company Research
Source: Seeking Alpha
This drug helps reduce cisplatin-induced ototoxicity in pediatric patients who are battling cancer. Pedmark is FDA-approved for pediatric patients =1 month, and it has shown good efficacy so far with patients. Pedmark is also the “first/only” in this drug class, and management believes they can eventually make Pedmark the standard-of-care to avoid hearing loss. Thus, despite FENC's concentrated risk on Pedmark, I feel their outlook for 2026 is quite compelling. So, I rate the stock a “Buy” at these levels. Daria Kulkova/iStock via Getty Images Fennec Pharmaceuticals Inc. ( FENC ) is a commercial-stage specialty pharmaceutical company that produces a drug for reducing cisplatin-induced ototoxicity (CIO). This asset is called Pedmark in the US, and Pedmarqsi in Europe (sodium thiosulfate injection). Cisplatin is a highly effective This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned,
Show less
Read more
Impact Snapshot
Event Time:
FENC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FENC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FENC alerts
High impacting Fennec Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
FENC
News
- Adherex Technologies (NASDAQ:FENC) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.MarketBeat
- Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell TumorsGlobeNewswire
- Fennec Pharmaceuticals Says its Phase 2/3 Trial of Pedmark in Japan Meets Primary Endpoint [Yahoo! Finance]Yahoo! Finance
- Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing LossGlobeNewswire
- Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
FENC
Earnings
- 11/13/25 - Beat
FENC
Sec Filings
- 12/9/25 - Form 8-K
- 12/5/25 - Form 4
- 12/5/25 - Form 144
- FENC's page on the SEC website